Global & Russia Cancer Therapeutics Market to 2031

The cancer therapeutics market in Russia has been experiencing consistent growth, fueled by a rising incidence of cancer, enhancements in healthcare infrastructure, and increased awareness around early diagnosis and treatment. According to GLOBOCAN data, Russia saw over 600,000 new cancer cases in 2023, alongside approximately 300,000 cancer-related deaths. The most common cancers include lung, breast, colorectal, and prostate cancers, with lung cancer posing a major challenge due to high smoking prevalence. Factors such as an aging population, lifestyle risks like smoking and alcohol use, and environmental pollution contribute to the growing cancer burden. In 2022, around 640,000 new cancer cases were reported, with colorectal and breast cancers being the most frequently diagnosed. That year, cancer-related deaths reached roughly 310,000, including about 83,693 new colorectal cancer cases, which accounted for 13.2% of all registered cases—highlighting the substantial need for effective cancer therapies.

The market is also benefiting from the increasing availability of advanced treatments. Targeted therapies, immunotherapies, and personalized medicine are becoming more accessible, with immuno-oncology drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) leading the way. Additionally, the growing use of biosimilars offers more affordable alternatives to costly biologics, expanding access to treatment. Biosimilars for medications such as Herceptin and Rituxan are becoming increasingly popular in Russia. Partnerships with major global pharmaceutical companies, including Roche and Pfizer, have further supported the introduction of innovative cancer therapies, broadening treatment options for patients in the country.